Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. entered into twelve exchange agreements with Streeterville Capital, LLC to partition $2,861,270.00 of the outstanding principal balance of the Streeterville Note into twelve separate secured promissory notes. These Partitioned Notes will be exchanged for an aggregate of up to 11,445,080 shares of Vivos' common stock, at an average exchange price of $0.25 per share. This transaction aims to reduce the company's outstanding debt.

Vivos Therapeutics, Inc. announced the issuance of a new US Patent, No. 12,697,190, which broadens the protection for its Vivos CARE oral medical device technology. This continuation patent builds upon a foundational patent from 2024, securing broader, design-independent claims. The company believes this strengthens its intellectual property position, making it more challenging for competitors to circumvent its innovations in treating obstructive sleep apnea (OSA), for which its devices have received unprecedented FDA clearances.

Vivos Therapeutics announced the issuance of US Patent No. 12,697,190, a continuation of a previously issued patent, which broadens the intellectual property protection for its Vivos CARE oral medical devices. These devices have received two unprecedented FDA 510K clearances for treating severe obstructive sleep apnea (OSA) in adults and moderate-to-severe OSA in children. The company believes this new patent strengthens its industry position and technological advantages, especially given the documented health risks and recalls associated with CPAP devices.

Vivos Therapeutics, Inc. announced the resignation of Bradford Amman as Chief Financial Officer and Secretary, effective July 31, 2026. Mr. Amman will transition to a non-executive role for 90 days as principal accounting officer, followed by a 180-day advisory period, receiving compensation including salary, advisory fees, and equity grants. Concurrently, Roman Franklin was appointed as the new CFO, effective July 31, 2026. Mr. Franklin, provided through a Master Services Agreement with The CFO Portal, LLC, brings over 20 years of finance and operations leadership experience to the company.

Vivos Therapeutics, Inc. completed a Private Investment in Public Equity (PIPE) offering, raising approximately $2.1 million. The company sold 3,608,496 units, each comprising Series A Convertible Preferred Stock, Common Stock warrants, and transferable subscription rights, to V-Co Investors 4 LLC and Bigger Capital Fund, LP. A significant portion of the funding, $1 million, came from the conversion of a prior bridge promissory note. The net proceeds will be used for general working capital.

Vivos Therapeutics announced compelling clinical data for its FDA-cleared Vida® oral appliance, demonstrating statistically significant improvement in insomnia severity in 100% of study participants. A single-site study of 37 adults showed an average Insomnia Severity Index (ISI) score reduction of approximately 65%, with all patients improving to no or subthreshold insomnia. This data suggests a major new commercial opportunity in the large global insomnia market, potentially expanding Vivos' addressable market beyond obstructive sleep apnea (OSA).

Vivos Therapeutics, Inc. has extended its strategic financing agreement with Streeterville Capital, LLC, pushing the deadline for completing a qualifying financing of at least $2.6 million from June 15, 2026, to August 31, 2026. This extension provides Vivos with additional time to raise equity and commence a planned rights offering. Streeterville Capital has reaffirmed its commitment to convert up to $4.5 million of its outstanding debt into a combination of preferred and common stock, contingent on Vivos raising the $2.6 million. The move is intended to strengthen Vivos' stockholders' equity and help maintain its Nasdaq listing compliance.

Vivos Therapeutics, Inc. announced its intention to file a registration statement for a proposed rights offering. The offering would distribute transferable subscription rights to shareholders as a dividend. Each right is expected to allow the holder to purchase one share of common stock at an exercise price based on a floor of $1.25 or a premium to the market price. The rights are intended to be listed for trading and exercisable for nine months, with a potential subsequent right upon exercise. The offering is subject to SEC effectiveness, shareholder approval, and other conditions.

Vivos Therapeutics, Inc. has entered into a Collaboration Agreement with South Palm Cardiovascular Associates, LLC (SPCVA) to form AIM Florida, LLC. This new entity will function as a management services organization providing administrative and non-clinical support to clinical entities focused on sleep apnea diagnosis and treatment. Vivos expects to hold at least 80% of AIM Florida's membership interests, with SPCVA holding up to 20%. The collaboration initially targets the Palm Beach County, Florida market and is seen as a scalable model for future expansion nationwide.

Vivos Therapeutics, Inc. announced its intention to file a registration statement with the SEC for a proposed rights offering. This offering aims to distribute transferable subscription rights to shareholders as a dividend, providing the company with additional capital for operations and general corporate purposes. Preliminary terms include an exercise price of the greater of $1.25 per share or 20% above market, a 9-month exercise period, and a subsequent 'exploding' right. The offering is subject to SEC effectiveness, shareholder approval, and other conditions, with no assurance of completion.